Related references
Note: Only part of the references are listed.A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2012)
Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions
Leonidas Benetatos et al.
ANNALS OF HEMATOLOGY (2011)
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
D. S. Boss et al.
ANNALS OF ONCOLOGY (2011)
Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS
Borje S. Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice
Ashley M. Ramirez-Herrick et al.
BLOOD (2011)
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
Pamela S. Becker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
E. Claire Dees et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
Anne M. Traynor et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
From Plk1 to Plk5 Functional evolution of Polo-like kinases
Guillermo de Carcer et al.
CELL CYCLE (2011)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors
Jennifer R. Diamond et al.
CLINICAL CANCER RESEARCH (2011)
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
David Olmos et al.
CLINICAL CANCER RESEARCH (2011)
Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression
Guillermo de Carcer et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia
S. S. Farag et al.
LEUKEMIA (2011)
Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracycline Toxicity
Edward Agura et al.
ONCOLOGIST (2011)
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells
Monika Raab et al.
NATURE COMMUNICATIONS (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process
Larissa Lordier et al.
BLOOD (2010)
Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe
June-Won Cheong et al.
CANCER LETTERS (2010)
A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway?
Annelies G. Renner et al.
CELL CYCLE (2010)
Polo-box domain: a versatile mediator of polo-like kinase function
Jung-Eun Park et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
Ralf-Dieter Hofheinz et al.
CLINICAL CANCER RESEARCH (2010)
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2010)
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics
Puneet Chopra et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy Results from an Open-Label, Randomized Phase II Clinical Trial
Martin Sebastian et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
Teresa Macarulla et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells
Martin Grundy et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias
A. S. Moore et al.
LEUKEMIA (2010)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus
Zdenek Andrysik et al.
NUCLEIC ACIDS RESEARCH (2010)
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Susanne M. A. Lens et al.
NATURE REVIEWS CANCER (2010)
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
Annelies G. Renner et al.
BLOOD (2009)
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
Nina Saban et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent
Amy W. Chun et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Aurora-A and hBora Join the Game of Polo
Libor Macurek et al.
CANCER RESEARCH (2009)
Theoretical model of treatment strategies for clear cell carcinoma of the ovary: Focus on perspectives
Shozo Yoshida et al.
CANCER TREATMENT REVIEWS (2009)
A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Roger B. Cohen et al.
CLINICAL CANCER RESEARCH (2009)
Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study
Linda Granowetter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer
Filippo Montemurro et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies
T. Ikezoe et al.
LEUKEMIA (2009)
A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid
Anita Ryningen et al.
LEUKEMIA RESEARCH (2009)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Polo-like kinases: conservation and divergence in their functions and regulation
Vincent Archambault et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology
Patrick Schoffski
ONCOLOGIST (2009)
The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low-Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Hanne Fredly et al.
CURRENT CANCER THERAPY REVIEWS (2009)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-tine therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
Stefan Faderl et al.
BLOOD (2008)
Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions
Yali Yang et al.
CANCER RESEARCH (2008)
Cell Growth Inhibition, G(2)/M Cell Cycle Arrest, and Apoptosis Induced by Chloroquine in Human Breast Cancer Cell Line Bcap-37
Pei-du Jiang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2008)
Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development
Tohru Takaki et al.
CURRENT OPINION IN CELL BIOLOGY (2008)
Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia
Christine Didier et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells
Noriyuki Takai et al.
GYNECOLOGIC ONCOLOGY (2008)
Molecular characterization of acute myeloid leukemia
Konstanze Doehner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors
Antonio Jimeno et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
Klaus Mross et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells
Anna Morena D'Alise et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Libor Macurek et al.
NATURE (2008)
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations
Zejuan Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Bora and the kinase Aurora A cooperatively activate the kinase Plk1 and control mitotic entry
Akiko Seki et al.
SCIENCE (2008)
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia
Xue-Fei Huang et al.
BLOOD (2008)
AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
Jing Yang et al.
BLOOD (2007)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
Polo-like kinases inhibited by Wortmannin - Labeling site and downstream effects
Yongsheng Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Histone deacetylase inhibitors in cancer treatment:: A review of the clinical toxicity and the modulation of gene expression in cancer cells
O. Bruserud et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2007)
Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients
Elisabeth Ersvaer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)
Mayumi Mori et al.
LEUKEMIA & LYMPHOMA (2006)
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors
Linda L. Garland et al.
CLINICAL CANCER RESEARCH (2006)
Megakaryocyte polyploidization is associated with decreased expression of polo-like kinase (PLK)
M. Yagi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
Protein lysine acetylation in normal and leukaemic haematopoiesis:: HDACs as possible therapeutic targets in adult AML
O Bruserud et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2006)
Small molecules keep mitotic kinases in check
Klaus Strebhardt
ACS CHEMICAL BIOLOGY (2006)
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia - The Japan adult leukemia study group AML97 study
S Miyawaki et al.
CANCER (2005)
Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review
JP Kline et al.
EXPERT OPINION ON PHARMACOTHERAPY (2005)
The Polo kinase Plk4 functions in centriole duplication
R Habedanck et al.
NATURE CELL BIOLOGY (2005)
Polo-like kinase 1 expression is a prognostic factor in human colon cancer
Wilko Weichert et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Getting in and out of mitosis with Polo-like kinase-1
MATM van Vugt et al.
ONCOGENE (2005)
Biochemical modulation of cytarabine triphosphate by clofarabine
T Cooper et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
S Faderl et al.
BLOOD (2005)
Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression
L Medina-Gundrum et al.
INVESTIGATIONAL NEW DRUGS (2005)
Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues
JA Winkles et al.
ONCOGENE (2005)
Polo-like kinase-2 is required for centriole duplication in mammalian cells
S Warnke et al.
CURRENT BIOLOGY (2004)
Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFβTrCP-dependent destruction of the APC inhibitor Emi1
DV Hansen et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Polo-like kinases and the orchestration of cell division
FA Barr et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome
Y Moshe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Aberrant quantity and localization of Aurora-B/AIM-1 and survivin during megakaryocyte polyploidization and the consequences of Aurora-B/AIM-1-deregulated expression
Y Zhang et al.
BLOOD (2004)
Role of Plk2 (Snk) in mouse development and cell proliferation
S Ma et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias
MC Petti et al.
ANNALS OF HEMATOLOGY (2003)
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers
HM Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers
T Takahashi et al.
CANCER SCIENCE (2003)
Active cyclin B1-Cdk1 first appears on centrosomes in prophase
M Jackman et al.
NATURE CELL BIOLOGY (2003)
Antitumor activity of 2-fluoro-2 '-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase
WB Parker et al.
CANCER GENE THERAPY (2003)
Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1
JP Yuan et al.
ONCOGENE (2002)
Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase
YJ Jang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cell cycle arrest and apoptosis induced by human polo-like kinase 3 is mediated through perturbation of microtubule integrity
Q Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Plk1 promotes nuclear translocation of human Cdc25C during prophase
F Toyoshima-Morimoto et al.
EMBO REPORTS (2002)
Acute myeloid leukemia in adults: where do we go from here?
CA Schiffer
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase
F Toyoshima-Morimoto et al.
NATURE (2001)
Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages
U Holtrich et al.
ONCOGENE (2000)
Share Paper
